Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
03/03/2026 13:03
March 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS BEGINS ENROLLING PHASE 1A/1B STUDY EVALUATING ARQ-234, A CD200R AGONIST, IN HEALTHY VOLUNTEERS AND ADULTS WITH ATOPIC DERMATITIS Source text: ID:nGNX7SCw2N Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf